Single-dose ciprofloxacin in the treatment of uncomplicated urinary tract infection in women
Abstract
In a randomised, double-blind trial two single-dose regimens of ciprofloxacin were evaluated for treatment of acute urinary tract infection (UTI) in women. Fifty-three women received 250 mg and 46 750 mg of ciprofloxacin. Seven days after treatment the eradication rate was 81.1% and 82.6% in the low and high dose groups respectively; the clinical cure rate at 28 days was 64.1% and 73.9% respectively. In women with recurrent UTI a significantly better response was found with the high dose regimen (92% versus 68%; p less than 0.001). It is concluded that a single 250 mg dose of ciprofloxacin is effective for treatment in most women with acute UTI, but in women with recurrent infection a 750 mg dose is preferable.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.